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Cytosolic DNA-sensing pathways that signal via Stimulator of
interferon genes (STING) mediate immunity to pathogens and also
promote autoimmune pathology in DNaseII- and DNaseIII-deficient
mice. In contrast, we report here that STING potently suppresses
inflammation in a model of systemic lupus erythematosus (SLE).
Lymphoid hypertrophy, autoantibody production, serum cytokine
levels, and other indicators of immune activation were markedly
increased in STING-deficient autoimmune-prone mice compared
with STING-sufficient littermates. As a result, STING-deficient
autoimmune-prone mice had significantly shorter lifespans than
controls. Importantly, Toll-like receptor (TLR)-dependent systemic
inflammation during 2,6,10,14-tetramethylpentadecane (TMPD)-
mediated peritonitis was similarly aggravated in STING-deficient
mice. Mechanistically, STING-deficient macrophages failed to ex-
press negative regulators of immune activation and thus were
hyperresponsive to TLR ligands, producing abnormally high levels
of proinflammatory cytokines. This hyperreactivity corresponds to
dramatically elevated numbers of inflammatory macrophages
and granulocytes in vivo. Collectively these findings reveal an
unexpected negative regulatory role for STING, having important
implications for STING-directed therapies.
STING | autoimmunity | IRF3 | lupus | TLRs
The detection of microbial DNA and the production of type IIFNs and proinflammatory cytokines is a central component
of host defense. The pattern recognition receptor Toll-like re-
ceptor (TLR) 9 detects DNA that accumulates in endolysosomal
compartments. In addition, newly described cytosolic DNA sen-
sors [cyclic guanosine monophosphate adenosine monophosphate
synthase (cGAS) and IFN inducible protein 16 (IFI16), among
others], detect DNA in the cytosol (1, 2). Each of these cytosolic
receptors converges on the multipass transmembrane endo-
plasmic reticulum-associated protein, Stimulator of IFN genes
(STING) (also known as “TMEM173,” “MPYS,” “MITA,” and
“ERIS”) (3, 4). STING is considered a critical hub, in cytosolic
DNA-sensing pathways, for innate responses directed against
numerous bacterial, viral, and parasitic pathogens (4). STING
activates host defense via induction of IFN-β through a well-
characterized pathway involving TBK1 and interferon regula-
tory factor 3 (IRF3) (4) and the production of the NF-κB–
driven cytokines TNF-α and IL-6 (3).
STING-dependent cytosolic sensors also detect endogenous
ligands, as first shown by polymorphisms in DNaseIII (3′ repair
exonuclease 1, Trex1) and related enzymes associated with DNA
degradation in patients with autoimmune diseases (5–7). Trex1-
deficient mice fail to degrade endogenous DNA, resulting in type I
IFN and proinflammatory cytokine production and sterile in-
flammation (8, 9). Importantly, STING deficiency limits inflammation
in the above model. However, its role in more common systemic
autoimmune diseases such as systemic lupus erythematosus (SLE) has
not yet been investigated.
To understand the impact of cytosolic DNA-sensing pathways
on SLE, we intercrossed STING-deficient mice with the SLE-
prone strain MRL.Faslpr and compared disease parameters in
STING-deficient and STING-sufficient Faslpr littermates. Our
analysis reveals a previously undescribed role for STING as
a negative regulator of TLR-mediated systemic autoimmunity, as
the STING−/− MRL.Faslpr mice developed more severe disease
and accelerated mortality. STING−/− mice subjected to 2,6,10,14-
tetramethylpentadecane (TMPD)-induced acute peritonitis also
display aggravated inflammation. Both models are driven by
endosomal TLRs; therefore it was particularly interesting to find
that STING-deficient macrophages were hyperresponsive to TLR
ligands. Collectively, our findings highlight unappreciated cross-
talk between TLR and cytosolic nucleic acid-sensing pathways in
maintaining immune homeostasis and raise a cautionary note
about targeting the STING pathway in chronic inflammation.
Results
STING Deficiency Accelerates Lymphocyte Accumulation and Activation
During Lupus. We generated two cohorts of autoimmune-prone
mice by intercrossing MRL.Faslpr mice with either STING- or
IRF3-deficient strains. This strategy led to the generation of F2
Significance
Systemic lupus erythematosus (SLE) is a chronic systemic auto-
immune disease that presents with a diverse array of clinical
symptoms and afflicts over 1.5 million Americans. Current
treatments involve immunosuppressive regimens associated
with debilitating and adverse effects. With the description of
a role for innate signaling in SLE, safe and efficient therapies
that block Toll-like receptors also have been stymied by the
relative short in vivo half lives of known inhibitors and the
dangerous outcome of complete MyD88 blockade. Key natural
regulators of the disease process are not well described but are
more likely to provide disease-specific therapeutics with fewer
adverse effects. In this study, we have identified a novel func-
tion for Stimulator of interferon genes as a suppressor of disease
and a target for future SLE therapeutics.
Author contributions: S.S. and A.M.-R. designed research; S.S., A.M.C., J.C., S.A.S., G.M.O.,
R.N., A.H.H., and C.M. performed research; S.S., G.M.O., R.N., K.N., C.M., L.J.B., M.J.S., and
A.M.-R. contributed new reagents/analytic tools; S.S., A.M.C., J.C., S.A.S., G.M.O., R.N., and
A.M.-R. analyzed data; and S.S., K.N., M.J.S., A.M.-R., and K.A.F. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
1A.M.C., J.C., S.A.S., and G.M.O. contributed equally to this work.
2A.M.-R. and K.A.F. contributed equally to this work.
3To whom correspondence may be addressed. Email: ann.rothstein@umassmed.edu or
kate.fitzgerald@umassmed.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1420217112/-/DCSupplemental.
E710–E717 | PNAS | Published online February 2, 2015 www.pnas.org/cgi/doi/10.1073/pnas.1420217112
mice that were Faslpr homozygotes and either STING−/− or IRF3−/−
(hereafter referred to as “STING/lpr” and “IRF3/lpr,” respectively)
as well as Faslpr/lpr STINGWT/WT or IRF3WT/WT (referred to as
“WT/lpr”). MRL.Faslpr mice routinely develop clinical features of
SLE associated with lymphoid hypertrophy by 20–24 wk of
age. However, by 16 wk of age the STING/lpr offspring displayed
markedly greater splenomegaly and lymphadenopathy and higher
splenocyte numbers than their STING-sufficient WT/lpr litter-
mates (Fig. 1 A and B and Fig. S1A). Faslpr/lpr STINGWT/− (Het)
littermates resembled the WT/lpr cohort. In contrast, the IRF3/
lpr mice did not show any alteration in disease progression
compared with control WT/lpr mice, and the splenic compart-
ments were identical in composition and size (Fig. 1 A and B).
Moreover, the frequency and total number of the unusual
CD4/CD8 double-negative (DN) TCRβ+ B220+ T-cell subset,
characteristic of Faslpr/lpr mice (10), was increased significantly in
the STING/lpr mice (Fig. 1C and Fig. S1B). STING/lpr mice also
had larger numbers of total and activated CD44+ CD69+ B220−
T cells and TCRβ− B cells (Fig. 1D and Fig. S1C). IRF3/lpr mice
did not display any overt expansion of naive or activated T or
B cells in their peripheral lymphoid organs (Fig. S1D). Impor-
tantly, STING−/− Fas-sufficient littermates (STING/WT) showed
no evidence of lymphoid hypertrophy or immune activation.
Additionally, the sex of the STING/lpr mice did not signifi-
cantly alter the severity of disease, because both male and female
STING/lpr mice showed similarly aggravated disease manifes-
tations (Fig. S1E). Thus, STING restricts unchecked immune
activation during systemic autoimmune disease and does so in
an IRF3-independent manner.
STING Deficiency Leads to Increased Autoantibody Production. An-
tinuclear antibodies (ANAs) are hallmarks of SLE (11). MRL.
Faslpr mice normally make autoantibodies against both RNA-
and DNA-associated autoantigens (12, 13). Importantly, STING/
lpr, but not IRF3/lpr, mice had more B220+ CD138+ plasma cells
than WT/lpr mice as well as a significantly greater incidence of
IgG class-switched antibody-producing cells as determined by
ELISPOT (Fig. 2A and Fig. S1F). To comprehensively compare
autoantibody specificity and titers of the STING/lpr and WT/lpr
mice, we used autoantigen microarrays (14). This analysis showed
an overall increase in autoantibody titers in the STING/lpr sera,
compared with WT/lpr littermates, especially with regard to auto-
antigens commonly associated with SLE such as DNA, histones,
chromatin, small nuclear ribonucleoproteins, C1q, granulocyte
markers, and extracellular matrix (Fig. 2B). Notably, the reactivity
of sera from the 16-wk-old STING/lpr mice was markedly elevated
compared with sera from age-matchedWT/lpr littermates and more
closely resembled the sera from 25-wk-old WT/lpr littermates.
STING Deficiency but Not IRF3 Deficiency Leads to Accelerated
Mortality, Lupus Nephritis, and Gross Morbidity in the MRL.Faslpr
Model. In agreement with their disease severity, STING/lpr
mice exhibited more extensive renal disease than their WT/lpr
littermates, as determined both by proteinuria and histological
examination of the kidneys at 16 wk of age (Fig. 3 A and B).
Histological examination of the STING/lpr kidneys showed
a greater degree of monocytic and lymphocytic infiltrates (Fig.
3B, a–c), substantial protein deposition, and thickening of the
basement membranes (Fig. 3B, d–f). Overall the STING/lpr
mice had significantly higher nephritis scores (Fig. 3C), whereas
the IRF3/lpr mice showed no signs of accelerated renal disease
(Fig. 3D). Importantly, more severe nephritis was associated
with significantly accelerated mortality in the STING/lpr
mice. The median age at death was 17.5 wk for STING/lpr
mice compared with 26 wk for the WT/lpr mice (P = 0.0037)
(Fig. 3E).
STING Deficiency but Not IRF3 Deficiency Leads to the Expansion of
Unusual Inflammatory Myeloid and Dendritic Cell Populations. Al-
though STING is expressed ubiquitously, its expression in mye-
loid cells is closely tied to its role in innate responses (3, 15).
Intriguingly, the number and activation status of myeloid cells
(CD11b+ or CD11c+) in the STING/lpr spleens was increased
greatly compared with WT/lpr littermates (Fig. 4 A and B and
Fig. S2A). Within the myeloid compartment, CD11b+ Ly6Chi
cells are considered a highly inflammatory class of monocytes,
and the Ly6Ghi/Ly6Cint subset consists of inflammatory neu-
trophils (16). Both subsets are characterized by their association
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Fig. 1. Lymphoid hypertrophy and increased immune activation in STING-deficient but not in IRF3-deficient autoimmune-prone mice. (A) Weights of spleens
and largest axillary lymph nodes (LN) from F2 littermates. (B) Total number of splenic cells. (C, Left) Identification of splenic TCRβ− B220+, B220− TCRβ+, and
B220+ TCRβ+ cells as determined by FACS analysis. (Right) Splenic percentages of B220+ TCRβ+ CD4− CD8− DN cells. (D) Percentage of activated splenic TCRβ+ T
cells (Left) and B220+ B cells (Right) based on CD44 and CD69 activation markers. P values for STING/lpr vs. WT/lpr are noted (one-way ANOVA). Mice were
16 wk old unless otherwise noted.
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with an inflammatory milieu and are thought to give rise to cells
that participate heavily in tissue destruction and remodeling (17,
18). Notably, STING/lpr mice showed a significant expansion and
activation of both Ly6Chi inflammatory monocyte (R1) and
Ly6Ghi neutrophil (R2) populations (Fig. 4C and Fig. S2 B and C).
Activated F4/80+ macrophage populations were increased simi-
larly (Fig. S2D). Importantly, neither macrophage nor neutrophil
populations were altered significantly in the IRF3/lpr mice
(Fig. S2E). There was also an increased frequency of F4/80−
Ly6Chi CD11c+ inflammatory dendritic cells (iDC) (Fig. 4C and
Fig. S2F). iDCs arise from the Ly6Chi inflammatory progenitor
pools and are a major source of proinflammatory cytokines in
models of tumor immunity (17, 18). The role of iDCs in SLE has
not been noted or described previously, and therefore their pres-
ence in the accelerated pathology in STING/lpr was unexpected.
The expansion of the Ly6C/G+ populations correlates with increased
systemic levels of neutrophil- and macrophage-derived chemo-
kines and cytokines including the M1-associated cytokines TNF-α
and IL-6 and chemokines (CCL2, CCL5, CXCL1, CCL3, and
CCL4) (Fig. 4D and Fig. S2G). Of note, IL-9 and IL-3 promote the
proliferation and differentiation of hematopoietic stem cells into
myeloid progenitor cells (19, 20), and increased systemic levels of
IL-9 and IL-3 correlate directly with the myeloid expansion
seen in STING/lpr mice (Fig. 4D). Together these data highlight
the previously unrecognized role that STING normally plays in
limiting the expansion and activity of pathogenic myeloid popu-
lations in systemic autoimmune diseases such as SLE.
STING Deficiency Results in the Increased Expression of IFN-Stimulated
Genes and IFN-α–Secreting Cell Populations. Type I IFNs have been
shown to play a significant role in SLE (21). Therefore it was
essential to determine whether the IFN signature was altered
in the STING/lpr mice. Gene-expression profiling of STING/lpr
and WT/lpr splenocytes showed a significant increase in the ex-
pression of IFN-stimulated genes (ISGs) in STING/lpr spleens
compared with WT/lpr littermates, as is consistent with disease
severity but paradoxical with STING deficiency (Fig. 4E). An up-
regulated ISG signature generally is indicative of increased levels
of type I IFNs and IFN-producing cells in the periphery. Plas-
macytoid dendritic cells (pDCs) are thought to be the major type
I IFN-producing cell (IPC) in both murine models of SLE and
in human patients, although other myeloid and lymphoid line-
age cells also are known contributors (22, 23). Importantly, the
number of pDCs identified as CD11cintSiglec-H+Bst2+ (Fig. S3A)
was increased significantly in the spleens from STING/lpr mice
but not in the IRF3/lpr spleens (Fig. S3B). By using intracellular
staining, we identified not only increased numbers of IFN-α–
producing pDCs but also IFN-α–producing Ly6Chi and Ly6Clo
monocytes in STING/lpr mice (Fig. 4 F and G and Fig. S3C).
IFN-α–producing Ly6Chi monocytes have been found at the site
of viral infections as well as in inflammatory diseases such as
colitis (18). However, the increase in IFN-α+ Ly6Clo cells was
surprising (Fig. 4G), because these subsets have not been iden-
tified previously as sources of type I IFN in SLE or other diseases.
This finding suggests that typical and atypical IFN-α–producing
pathways are significantly dysregulated in the absence of STING.
TMPD-Induced Peritonitis Is Amplified by STING Deficiency. Several
key features of SLE are recapitulated by the i.p. injection of the
hydrocarbon oil TMPD (also known as “pristane”). These fea-
tures include a type I IFN signature, ANAs, and glomerulone-
phritis (24, 25). Importantly, TMPD-induced autoimmunity is
dependent upon TLR7 and type I IFNs (26). Pristane injection
of C57/Bl6 mice results in an early and persistent peritoneal
inflammation and the recruitment of TLR7hi Ly6Chi monocytes,
a potential source of type I IFNs, in this model (25). We thus
sought to determine if TMPD-induced, TLR-dependent in-
flammation is also modulated by STING. The extravasation of
inflammatory monocytes and granulocytes into the peritoneal
cavity following TMPD administration was entirely dependent
on endosomal TLRs, because no evidence of inflammation oc-
curred in pristane-treated Unc93b3d/3d mice (Fig. 5A). In com-
parison, STING−/− mice showed greater accumulation of total
cells, CD11b+ myeloid cells, and especially CD11b+ Ly6Chi in-
flammatory monocytes. The expression of ISGs (IRF7 and Mx1)
was also increased in the peritoneal exudate cells (PECs) from
STING−/− mice but not Unc93b3d/3d mice (Fig. 5B), again impli-
cating type I IFN in pathology. Although there was no significant
increase in the number of Ly6Cint Ly6Ghi granulocytes in the peri-
toneum, the percentage of Ly6Cint Ly6Ghi granulocytes was signif-
icantly higher in the spleens of the TMPD-injected STING−/− mice
than in controls (Fig. 5C). The accumulation of inflammatory
granulocytes in the spleens of pristane-treated mice at 6 mo post-
injection has been reported previously (16); however, to our
knowledge, this is the first report of such an early signature of
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Fig. 2. Increased numbers of antibody-producing cells and accelerated au-
toantibody production in STING-deficient autoimmune-prone mice. (A, Left)
Percentage of B220+ CD138+ plasma cells as determined by FACS analysis.
(Right) Total number of antibody-forming cells (AFCs) quantified by IgG
ELISPOT analysis. Data are presented as mean ± SEM. P values as noted
(Student’s t test). (B) Autoantibody specificity and titers were determined
by binding of sera from WT/lpr (n = 5) and STING/lpr (n = 9) littermates to a
predefined autoantigen array. Data are presented as a heatmap summarizing
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Mice were 16 or 25 wk old; asterisks indicate 25-wk-old mice.
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systemic inflammation. These data document a second example
in which STING negatively regulates a TLR-dependent inflam-
matory response.
Macrophages Derived from STING-Deficient Mice Are Hyperresponsive
to TLR7 and TLR9 Ligands. In all SLE models evaluated to date,
immune activation depends on the ability of endogenous TLRs to
recognize nucleic acid-associated autoantigens (25, 27). There-
fore, we reasoned that STING/lpr-derived macrophages could be
inherently more reactive to such autoantigens via TLR7- and/or
TLR9-dependent pathways. To test this possibility directly, bone
marrow-derived macrophages (BMMs) from STING/lpr and
WT/lpr mice were stimulated with TLR7 and TLR9 ligands.
As expected, STING/lpr macrophages failed to produce the
proinflammatory cytokines TNF-α and IL-6 in response to
immune-stimulatory DNA (ISD) known to activate STING-
dependent cytosolic DNA sensors (3). However, these same cells
were hyperresponsive to the TLR9 ligand CpGB ODN and the
TLR7 ligand CLO97. Additionally, macrophages from STING/WT
littermates were similarly hyperresponsive to TLR7 and TLR9
ligands (Fig. 6A). To confirm that this increase actually was caused
by STING deficiency alone and not by other MRL-associated
genes, we also compared STING-deficient and STING-sufficient
C57BL/6 BMMs (Fig. S4A). Again the STING−/− BMMs were
hyperresponsive to TLR7 and TLR9 ligands, despite impaired
responses to ISD or B-form DNA (pdAdT). Moreover, STING−/−
BMMs made significantly more IL-6 in response to limiting con-
centrations of TLR7/9 ligands (Fig. 6B) as well as additional TLR
ligands (Fig. S4B). In addition, TLR3 stimulation of STING−/−
BMMs resulted in elevated levels of IFN-β (Fig. S4C). Thus, more
than one pathway, downstream of TLRs, is modified by STING
deficiency.
STING Deficiency but Not IRF3 Deficiency Results in Reduced Levels of
Known Negative Regulators of TLR Signaling. STING deficiency
could lead to amplified activation of TLR-dependent macro-
phage responses either by increasing the level of TLR expression
or by decreasing negative regulation of TLR signaling. We
compared basal levels of endosomal TLRs in WT, STING−/−,
WT/lpr, and STING/lpr BMMs but found no difference in
TLR3, TLR7, or TLR9 expression (Fig. S5A). Surprisingly,
unstimulated STING−/− BMMs had dramatically decreased ex-
pression of several well-characterized negative regulators of
TLR signaling, including A20 and suppressor of cytokine sig-
naling 1 (SOCS1) and 3 (SOCS3), compared with WT controls
(Fig. 6 C and D). Importantly, these genes are not regulated
through an IRF3-dependent mechanism, because IRF3−/−
BMMs did not display any change in basal expression levels of
these critical negative regulators (Fig. 6C). Levels of A20,
SOCS1, and SOCS3 were also decreased substantially in acti-
vated STING−/− BMMs (Fig. S5B). Similar analysis of STING/
lpr- and WT/lpr-derived BMMs revealed significantly attenuated
A20, SOCS1, and SOCS3 levels basally and in response to TLR
ligands (Fig. 6E and Fig. S5C). Furthermore, gene profiling of
STING/lpr and WT/lpr splenic tissue also revealed a significant
decrease in the expression of these negative regulators (Fig. 6E).
To confirm that the expression of these negative regulators was
regulated directly by STING, we determined the effect of STING
overexpression on these genes. We found that stable over-
expression of STING in RAW264.7 macrophage cells resulted in
elevated basal levels of A20, SOCS1, and SOCS3, further dem-
onstrating STING-dependent regulation of these components
(Fig. 6G). Moreover, ectopic expression of STING reduced the
production of TNF-α and IL-6 in response to TLR ligands but
not in response to cytosolic DNA ligands (Fig. S5D).
Secreted negative regulators of immune responses also con-
tribute to self-tolerance. Recent studies have shown that myeloid
cell production of Indoleamine 2,3-deoxygenase-1 (IDO-1),
particularly by dendritic cells (DCs), promotes the conversion
and expansion of regulatory T cells (28). When spleen sections
from 16-wk-old STING/lpr and WT/lpr littermates were stained
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with anti–IDO-1 antibody, spleens from STING/lpr mice had
greatly reduced IDO-1 levels compared with age-matched lit-
termate controls (Fig. 6G). Because IDO-1 is thought to control
the generation of Treg cells, we determined the number of Treg
cells in STING/lpr and control mice. We found that STING/lpr
mice had significantly lowered percentages of activated CD4+
CD25+ FOXP3+ Treg cells and also tended toward lowered per-
centages of CD4+ FOXP3+ Treg cells in axillary lymph nodes (Fig.
6H). These data, along with other recent studies (29), explain how
immune suppression in STING−/− animals may be systemically
compromised. Overall, these data strongly indicate that in the
context of an SLE autoimmune-prone background, STING-
deficient myeloid cells mount an amplified response to nucleic
acid-associated autoantigens caused by the reduced expression
of molecules that directly or indirectly limit immune activation.
Discussion
Foreign DNA can trigger both endosomal TLR9 and cytosolic
STING-dependent DNA sensors, leading to the robust production
of type I IFNs and other proinflammatory cytokines important in
the clearance of microbial pathogens. Chronic stimulation of these
sensors by endogenous ligands also provokes debilitating auto-
inflammatory or autoimmune diseases such as seen in mice or
humans with compromised capacities to degrade DNA. In con-
trast to experimental settings where STING provokes inflamma-
tion, our studies show that STING can attenuate inflammation
in both a chronic systemic autoimmune disease and in an acute
inflammatory response that is dependent on TLR-mediated de-
tection of endogenous ligands. STING-deficient MRL/lpr mice
develop a dramatically accelerated disease profile character-
ized by the expansion and activation of both the lymphoid and
myeloid compartments, increased numbers of type I IFN-pro-
ducing cells, elevated autoantibody titers, and a shorter lifespan.
Similar to our findings in the MRL/lpr model, STING deficiency
exacerbated TMPD-induced inflammation, a condition also
associated with type I IFNs and TLR-activated Ly6Chi mono-
cytes (24, 26).
Nonautoimmune-prone STING-deficient mice do not exhibit
any evidence of systemic autoimmunity. Therefore, the exacer-
bated disease phenotype of the STING-deficient MRL/lpr mice
likely results from the failure to constrain aberrantly activated
TLR signaling cascades responsible for disease. Intriguingly, A20-,
SOCS1-, or SOCS3-deficient mice exhibit phenotypes similar to
our STING/lpr mice (30, 31). In addition to impaired expression
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of these negative regulators of TLR activation, STING/lpr mice
also failed to express the secreted immunosuppressive protein
IDO-1. Previous studies documented IDO-1 expression in the
spleens of prediseased MRL.Faslpr mice and its reduced expres-
sion with disease progression (32). Moreover, treatment with
an IDO-1 inhibitor 1-methyl tryptophan (1-MT) accelerates
disease in the MRL.Faslpr mice, implicating IDO-1 in the
negative regulation of immune activation associated with autoim-
munity. Because IDO-1 is potently induced by TLR-dependent
and -independent pathways and regulates the expansion of
Tregs, it is a critical factor in limiting disease severity (28). Recently,
Huang et al. (33) showed that IDO-1 expression in DCs is at-
tenuated in the absence of STING, leading to increased IL-6
production by STING−/− DCs in response to apoptotic cells.
We now show decreased IDO-1 levels and a corresponding
decrease in Treg cells in STING-deficient SLE-prone mice.
These conditions are likely to contribute to the exacerbated disease
phenotype.
A seemingly unrelated outcome of disease in the STING/lpr
mice is the large number of monocytic cells in secondary lym-
phoid tissues. However, monocyte egress from the bone marrow
and local proliferation is a known consequence of TLR en-
gagement (34). Whether increased TLR activity also contributes
to the excess production of the hematopoiesis-modulating cytokines
IL-9 and IL-3, thereby further promoting myeloid expansion in
STING/lpr animals, remains to be determined.
Although an increase in proinflammatory cytokines in re-
sponse to apoptotic cells and TLR9 and TLR3 ligands has been
noted previously in STING−/− macrophages by other inves-
tigators (33, 35), the significance of this dysregulation of TLR
signaling was not addressed further or extended to other TLRs.
Previous studies have focused largely on the ability of STING to
engage the TBK1–IRF3 signaling pathway. It is critical to note
that, thus far, IRF3 has been implicated only in the transcription
of type I IFNs (36). Furthermore, IRF3 deficiency does not af-
fect the disease course of MRL/lpr, and therefore it is likely that
a STING-dependent but IRF3-independent pathway mediates
the effects we observed. Intriguingly, some evidence exists for the
role of IRF3/7 heterodimers in inducing type I IFNs downstream
of STING (37). However, a definitive role for IRF7 has not yet
been evaluated in lupus and may contribute to lupus pathology
downstream of both STING and TLRs. Prior studies have shown
that cytosolic DNA can induce the expression of proinflammatory
cytokines through the activation of an NF-κB–dependent pathway
downstream of STING (3). Intriguingly, we show that the basal
expression of negative regulators of TLR signaling such as A20,
SOCS1, and SOCS3, known NF-κB target genes, is down-regu-
lated significantly in STING−/− cells but not in IRF3−/− cells.
These data further highlight the contribution of NF-κB signaling
downstream of STING under homeostatic conditions and point to
a constitutive role of this pathway in immune regulation. It is
possible that other transcription factors, such as IRFs and STATs,
may be engaged downstream of STING, but likely candidates
IRF5, IRF1, STAT1, and STAT6 have previously been shown to
promote lupus pathology (38–42), in contrast to the suppressive
role of STING documented in this study. Thus, it is unlikely that
transcriptional activity of any of these factors contributes to a
STING-dependent suppressive pathway.
Dysregulation of TLR signaling is a recurrent theme in the
development and severity of systemic autoimmune diseases such
as SLE. Both TLR7 and TLR9 activation have been linked to
the pathogenesis of SLE (43). However, despite similar tissue
expression and signaling pathways, deficiency of these TLRs on
an MRL.Faslpr background, as well as other autoimmune-prone
strains, has revealed opposing roles for these TLRs in SLE.
Although opposing roles of TLR7/9 in autoimmunity have been
known for some time, mechanistic insight into their cross-regula-
tion is still lacking. In many ways the exacerbated disease we ob-
served in STING/lpr mice resembles that reported for TLR9/lpr
mice; both strains show elevated expression of ISGs and marked
expansion and activation of lymphocyte compartments. Our studies
now suggest that modulation of negative regulators of signaling
may be a common mechanism of cross-regulation applicable to
TLRs as well as other innate pathways during autoimmunity.
It is conceivable that the negative regulatory role of STING
we observed is independent of its role in DNA sensing and
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represents a homeostatic role for STING resulting from sto-
chastic dimerization. Alternatively, low levels of cytosolic DNA,
perhaps through reactivated retro-elements, may account for the
homeostatic involvement of STING. The precise mechanism by
which STING regulates homeostasis remains an open question.
Although loss-of-function polymorphisms for STING are known,
they have not yet been linked to any human diseases (44). Loss-
of-function mutations in Trex1, presumably leading to hyper-
activation of STING, are associated with Aicardi–Goutieres
syndrome. Moreover, gain-of-function mutations in STING
are now linked to a class of vascular and pulmonary in-
flammatory syndromes as well as familial systemic diseases (45,
46). Together, these clinical observations have identified the
STING pathway as a potential therapeutic target. Our data
now raise a cautionary note regarding the use of such thera-
peutics, because they may have unintended consequences and
perturb a carefully orchestrated balance between cytosolic and
endosomal signaling cascades.
Experimental Procedures
Generation and Characterization of Autoimmune STING-Deficient Mice. The
University of Massachusetts Medical School and Yale Institutional Animal
Care and Use Committees approved all animal work.
STING−/− mice (3) (from G. Barber, University of Miami, Coral Gables,
FL) and IRF3−/− mice (47) were crossed to Fas-deficient, lupus-prone MRL/
Mplpr/lpr mice (Jackson Laboratory). A controlled F2 intercross between
heterozygote STING+/− lpr/+ littermates was used to generate STING-de-
ficient lupus-prone mice homozygous for deficiency in Fas as well as
STING (STING/lpr, n = 17–20) or wild type for STING (WT/lpr, n = 9–15). The
heterogeneous genetic composition of the F2 generation was controlled
by the use of large cohorts of littermates. Most mice were analyzed at 16 wk
of age; three STING/lpr mice and three WT/lpr mice were analyzed at 25 wk
of age.
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Fig. 6. STING regulates responsiveness to TLR ligands and controls the expression of critical negative regulators of innate signaling. (A) Levels of TNF-α and IL-6
secreted by BMMs from WT/lpr, STING/lpr, WT/WT, and STING/WT mice in response to TLR9 (CpGB, 5 μM), TLR7 (CLO97, 300 ng/mL), and ISD (3 μM) ligands.
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pression in C57BL/6, STING−/−, and IRF3−/− BMMs and is transformed by a log2 function. (D) Real-time PCR analysis of A20, SOCS1, and/or SOCS3 mRNA from
unstimulated C57BL/6 (black bars) and STING−/− (gray bars) BMMs. (E, Left) Real-time PCR analysis of A20, SOCS1, and/or SOCS3 mRNA WT/lpr (black bars) and
STING/lpr (gray bars) BMMs. (Right) Nanostring mRNA profiling of splenic tissue from WT/lpr and STING/lpr mice. The analysis compares relative basal ex-
pression levels of A20, SOCS1, and SOCS3 in WT/lpr mice (n = 4; black bars) and STING/lpr (n = 6; gray bars) mice. (F) RT-PCR analysis of A20, SOCS1, and SOCS3
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t test; P values in G were calculated using two-way ANOVA.
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Statistical Analysis. Experiments are reported as the means ± SEM/SD. Sta-
tistical comparisons were made using a Student t test and GraphPad Prism
software (GraphPad Software) for bivariate studies and one-way ANOVA for
multivariate studies. P values for all criteria measured are reported, and
P values <0.05 were considered statistically significant.
Please see SI Experimental Procedures for more information on the
methods used in this study.
ACKNOWLEDGMENTS. We thank Brian G. Monks, Zhaozhao Jiang, Tara
Robidoux, and Numana Bhat for contributions at critical phases of experi-
mentation. This work was supported by Alliance for Lupus Research Grant
ALR 260146 (to S.S.), National Institutes of Health (NIH) Grants AI093752 (to
K.A.F.), AR050256 (to A.M.-R.), and AI101048 (to L.J.B.). Support for A.M.C. was
provided by NIH Grant 2T32GM07205. Support for J.C., S.A.S., and G.M.O. was
provided by NIH Grant 5T32A1095213.
1. Sun L, Wu J, Du F, Chen X, Chen ZJ (2013) Cyclic GMP-AMP synthase is a cytosolic DNA
sensor that activates the type I interferon pathway. Science 339(6121):786–791.
2. Unterholzner L, et al. (2010) IFI16 is an innate immune sensor for intracellular DNA.
Nat Immunol 11(11):997–1004.
3. Ishikawa H, Barber GN (2008) STING is an endoplasmic reticulum adaptor that facili-
tates innate immune signalling. Nature 455(7213):674–678.
4. Burdette DL, Vance RE (2013) STING and the innate immune response to nucleic acids
in the cytosol. Nat Immunol 14(1):19–26.
5. Shin HD, et al. (2005) DNase II polymorphisms associated with risk of renal disorder
among systemic lupus erythematosus patients. J Hum Genet 50(3):107–111.
6. Crow YJ, et al. (2006) Mutations in the gene encoding the 3′-5′ DNA exonuclease
TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat Genet 38(8):917–920.
7. Lee-Kirsch MA, et al. (2007) Mutations in the gene encoding the 3′-5′ DNA exo-
nuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 39(9):
1065–1067.
8. Kawane K, et al. (2006) Chronic polyarthritis caused by mammalian DNA that escapes
from degradation in macrophages. Nature 443(7114):998–1002.
9. Stetson DB, Ko JS, Heidmann T, Medzhitov R (2008) Trex1 prevents cell-intrinsic ini-
tiation of autoimmunity. Cell 134(4):587–598.
10. Seong CS, Varela-Ramirez A, Aguilera RJ (2006) DNase II deficiency impairs innate
immune function in Drosophila. Cell Immunol 240(1):5–13.
11. Craft JE (2011) Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci
Transl Med 3(73):ps9.
12. Christensen SR, et al. (2005) Toll-like receptor 9 controls anti-DNA autoantibody
production in murine lupus. J Exp Med 202(2):321–331.
13. Christensen SR, et al. (2006) Toll-like receptor 7 and TLR9 dictate autoantibody
specificity and have opposing inflammatory and regulatory roles in a murine model
of lupus. Immunity 25(3):417–428.
14. Li L, et al. (2012) Murine lupus strains differentially model unique facets of human
lupus serology. Clin Exp Immunol 168(2):178–185.
15. Ahn J, Gutman D, Saijo S, Barber GN (2012) STING manifests self DNA-dependent
inflammatory disease. Proc Natl Acad Sci USA 109(47):19386–19391.
16. Bossaller L, et al. (2013) Overexpression of membrane-bound fas ligand (CD95L) ex-
acerbates autoimmune disease and renal pathology in pristane-induced lupus.
J Immunol 191(5):2104–2114.
17. Rivollier A, He J, Kole A, Valatas V, Kelsall BL (2012) Inflammation switches the dif-
ferentiation program of Ly6Chi monocytes from antiinflammatory macrophages to
inflammatory dendritic cells in the colon. J Exp Med 209(1):139–155.
18. Shi C, Pamer EG (2011) Monocyte recruitment during infection and inflammation. Nat
Rev Immunol 11(11):762–774.
19. Goswami R, Kaplan MH (2011) A brief history of IL-9. J Immunol 186(6):3283–3288.
20. Reddy EP, Korapati A, Chaturvedi P, Rane S (2000) IL-3 signaling and the role of Src
kinases, JAKs and STATs: A covert liaison unveiled. Oncogene 19(21):2532–2547.
21. Theofilopoulos AN (2012) TLRs and IFNs: Critical pieces of the autoimmunity puzzle.
J Clin Invest 122(10):3464–3466.
22. Pascual V, Farkas L, Banchereau J (2006) Systemic lupus erythematosus: All roads lead
to type I interferons. Curr Opin Immunol 18(6):676–682.
23. Banchereau J, Pascual V (2006) Type I interferon in systemic lupus erythematosus and
other autoimmune diseases. Immunity 25(3):383–392.
24. Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L (2009) Induction of autoimmunity by
pristane and other naturally occurring hydrocarbons. Trends Immunol 30(9):455–464.
25. Lee PY, et al. (2008) TLR7-dependent and FcgammaR-independent production of type
I interferon in experimental mouse lupus. J Exp Med 205(13):2995–3006.
26. Savarese E, et al. (2008) Requirement of Toll-like receptor 7 for pristane-induced
production of autoantibodies and development of murine lupus nephritis. Arthritis
Rheum 58(4):1107–1115.
27. Green NM, Marshak-Rothstein A (2011) Toll-like receptor driven B cell activation in
the induction of systemic autoimmunity. Semin Immunol 23(2):106–112.
28. Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of
immune responses. Trends Immunol 34(3):137–143.
29. Lemos H, et al. (2014) Activation of the STING adaptor attenuates experimental au-
toimmune encephalitis. J Immunol 192(12):5571–5578.
30. Coornaert B, Carpentier I, Beyaert R (2009) A20: Central gatekeeper in inflammation
and immunity. J Biol Chem 284(13):8217–8221.
31. Dalpke A, Heeg K, Bartz H, Baetz A (2008) Regulation of innate immunity by sup-
pressor of cytokine signaling (SOCS) proteins. Immunobiology 213(3-4):225–235.
32. Ravishankar B, et al. (2012) Tolerance to apoptotic cells is regulated by indoleamine
2,3-dioxygenase. Proc Natl Acad Sci USA 109(10):3909–3914.
33. Huang L, et al. (2013) Cutting edge: DNA sensing via the STING adaptor in myeloid
dendritic cells induces potent tolerogenic responses. J Immunol 191(7):3509–3513.
34. Shi C, et al. (2011) Bone marrow mesenchymal stem and progenitor cells induce
monocyte emigration in response to circulating toll-like receptor ligands. Immunity
34(4):590–601.
35. Ishikawa H, Ma Z, Barber GN (2009) STING regulates intracellular DNA-mediated, type
I interferon-dependent innate immunity. Nature 461(7265):788–792.
36. Tamura T, Yanai H, Savitsky D, Taniguchi T (2008) The IRF family transcription factors
in immunity and oncogenesis. Annu Rev Immunol 26:535–584.
37. Sharma S, et al. (2011) Innate immune recognition of an AT-rich stem-loop DNA motif
in the Plasmodium falciparum genome. Immunity 35(2):194–207.
38. Niewold TB, et al. (2008) Association of the IRF5 risk haplotype with high serum
interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum
58(8):2481–2487.
39. Tada Y, et al. (2011) Interferon regulatory factor 5 is critical for the development of
lupus in MRL/lpr mice. Arthritis Rheum 63(3):738–748.
40. Yu HH, et al. (2010) Interleukin 4 and STAT6 gene polymorphisms are associated with
systemic lupus erythematosus in Chinese patients. Lupus 19(10):1219–1228.
41. Singh RR, et al. (2003) Differential contribution of IL-4 and STAT6 vs STAT4 to the
development of lupus nephritis. J Immunol 170(9):4818–4825.
42. Reilly CM, et al. (2006) Interferon regulatory factor-1 gene deletion decreases glo-
merulonephritis in MRL/lpr mice. Eur J Immunol 36(5):1296–1308.
43. Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat
Rev Immunol 6(11):823–835.
44. Jin L, et al. (2011) Identification and characterization of a loss-of-function human
MPYS variant. Genes Immun 12(4):263–269.
45. Jeremiah N, et al. (2014) Inherited STING-activating mutation underlies a familial
inflammatory syndrome with lupus-like manifestations. J Clin Invest 124(12):
5516–5520.
46. Liu Y, et al. (2014) Activated STING in a vascular and pulmonary syndrome. N Engl J
Med 371(6):507–518.
47. Sato M, et al. (2000) Distinct and essential roles of transcription factors IRF-3 and IRF-7
in response to viruses for IFN-alpha/beta gene induction. Immunity 13(4):539–548.
Sharma et al. PNAS | Published online February 2, 2015 | E717
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
PN
A
S
PL
U
S
